RecruitingNCT07061288
Safety and medicine levels of injectable KarXT in schizophrenia
About this title
Read the official source — NCT07061288This study evaluates the safety of KarXT for people with schizophrenia.
Medication studyAges 18–55United States
Understand this study
What is this study about?
This study evaluates the safety of KarXT for people with schizophrenia.
Who could participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
- Listed locations
- Los Alamitos and 7 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
What to know before participating
A point to clarify
This summary does not cover all risks or eligibility requirements. What risks or changes to my care would apply to me?
Things to check before joining
Study start dateStarted: September 3, 2025
- Recruitment status
- Recruiting
- Enrollment listed in the registry
- 131
- Sponsor
- Bristol-Myers Squibb
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 55 Years
- Official registry ID
- NCT07061288
- Official title
Show the full official title
An Open-label, Phase 1, Dose-Finding Study to Characterize the Safety, Tolerability, and Pharmacokinetics of a Long-Acting Injectable KarXT Formulation in Participants With Schizophrenia
Recruitment & locations
Currently recruitingA study may be recruiting, but some locations may no longer be accepting participants. Confirm availability with the research team.
Los Alamitos · Hollywood · Miami Lakes
5 more locations
- Atlanta
- Decatur
- Chicago
- Marlton
- Austin
Interested in joining this study?
Questions about this study
What is this study about?
This study evaluates the safety of KarXT for people with schizophrenia.
Who is behind this study?
The study sponsor is Bristol-Myers Squibb, a pharmaceutical company.
Does this study involve medication?
Yes. The study involves medication, including KarXT.
Who can participate?
This study is for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria apply.
Is this study still recruiting?
The registry lists this study as recruiting.
